TAVNEOS
Peakavacopan
NDAORALCAPSULE
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Mechanism of Action
Complement 5a Receptor Antagonists
Pharmacologic Class:
Complement 5a Receptor Antagonist
Clinical Trials (5)
TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Started Jul 2026
30 enrolled
Granulomatosis With PolyangiitisWegener'sGPA
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
Started Oct 2024
20 enrolled
Vasculitis
A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)
Started Jul 2024
13 enrolled
End-Stage Renal Disease (ESRD)
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Started Feb 2024
300 enrolled
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin
Started Jun 2022
32 enrolled
Healthy Volunteers
Loss of Exclusivity
LOE Date
Nov 27, 2039
167 months away
Patent Expiry
Nov 27, 2039
Exclusivity Expiry
Oct 7, 2028